- Home
- TNON vs LYRA Comparison
TNON vs LYRA Comparison
Compare TNON & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- LYRA
- Stock Information
- Founded
- TNON 2012
- LYRA 2005
- Country
- TNON United States
- LYRA United States
- Employees
- TNON N/A
- LYRA N/A
- Industry
- TNON Medical Specialities
- LYRA Medical/Dental Instruments
- Sector
- TNON Health Care
- LYRA Health Care
- Exchange
- TNON Nasdaq
- LYRA Nasdaq
- Market Cap
- TNON 11.5M
- LYRA 11.3M
- IPO Year
- TNON 2022
- LYRA 2020
- Fundamental
- Price
- TNON $1.24
- LYRA $6.37
- Analyst Decision
- TNON Strong Buy
- LYRA Hold
- Analyst Count
- TNON 2
- LYRA 1
- Target Price
- TNON $5.50
- LYRA $16.00
- AVG Volume (30 Days)
- TNON 1.0M
- LYRA 49.1K
- Earning Date
- TNON 11-12-2025
- LYRA 11-11-2025
- Dividend Yield
- TNON N/A
- LYRA N/A
- EPS Growth
- TNON N/A
- LYRA N/A
- EPS
- TNON N/A
- LYRA N/A
- Revenue
- TNON $2,947,000.00
- LYRA $770,000.00
- Revenue This Year
- TNON $43.52
- LYRA N/A
- Revenue Next Year
- TNON $82.14
- LYRA $106.28
- P/E Ratio
- TNON N/A
- LYRA N/A
- Revenue Growth
- TNON N/A
- LYRA N/A
- 52 Week Low
- TNON $0.85
- LYRA $3.81
- 52 Week High
- TNON $5.85
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- TNON 53.89
- LYRA 39.68
- Support Level
- TNON $1.12
- LYRA $6.25
- Resistance Level
- TNON $1.44
- LYRA $7.30
- Average True Range (ATR)
- TNON 0.08
- LYRA 0.60
- MACD
- TNON 0.00
- LYRA -0.13
- Stochastic Oscillator
- TNON 45.71
- LYRA 8.98
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.